Myriad Genetics Inc (MYGN) Gross Profit Margin starting from the second quarter 2026 to second quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Myriad Genetics Inc   (NASDAQ: MYGN)


Myriad Genetics Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MYGN Gross Profit Margin (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3 		(Jun 30 2025)
Q2
Y / Y Revenue Change -10.39 %
Seq. Revenue Change -4.46 %
Revenue In Millions $190.70
Gross Profit Margin 66.6 %
Gross Profit Margin Total Ranking # 1048
Gross Profit In Millions $127.00
Y / Y Gross Profit Change -16.34 %
Seq. Gross Profit Change -7.7 %


Commenting Second Quarter 2026 Gross Profit Margin
Myriad Genetics Inc experienced contraction in Gross Profit by -7.7 % to $191 millions and Revenue by -4.46 %, while Gross Profit Margin fell to 66.6 %, below company*s average Gross Profit Margin.


Observing second quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry Myriad Genetics Inc has achieved highest Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 1048, from total ranking in the previous quarter at 1074.
Learn about Gross Margin
MYGN's Gross Profit Margin second quarter 2026 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 1
Healthcare Sector # 192
Overall # 1040

Gross Profit Margin Statistics
High Average Low
89.62 % 77.02 % 53.3 %
(Mar 31 2012)   (Jun 30 2019)


MYGN Gross Income Trends • More of MYGN's Profitabilty Ratios • MYGN Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
MYGN's Cumulative Gross Profit Margin
In Vitro & In Vivo Diagnostic Substances Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
MYGN's Gross Profit Margin Profitability versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for MYGN's Competitors
Gross Profit Margin Profit Margin for Myriad Genetics Inc 's Suppliers
Gross Profit Margin Profit Margin for MYGN's Customers

You may also want to know
MYGN's Annual Growth Rates MYGN's Profitability Ratios MYGN's Asset Turnover Ratio MYGN's Dividend Growth
MYGN's Roe MYGN's Valuation Ratios MYGN's Financial Strength Ratios MYGN's Gross Profit Growth
MYGN's Roa MYGN's Inventory Turnover Ratio MYGN's Growth Rates MYGN's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jun 30 2026, within In Vitro & In Vivo Diagnostic Substances Industry Gross Profit MarginJun 30 2026 MRQ Gross ProfitJun 30 2026 MRQ Revenue
Myriad Genetics Inc   66.60 %$ 127.000  Millions$ 190.700  Millions
Insight Molecular Diagnostics Inc   65.69 %$ 0.157  Millions$ 0.239  Millions
Idexx Laboratories Inc  64.04 %$ 779.087  Millions$ 1,216.585  Millions
Lantheus Holdings Inc   62.30 %$ 241.855  Millions$ 388.180  Millions
Neogen Corporation  47.91 %$ 108.062  Millions$ 225.536  Millions
Quidelortho Corp  43.26 %$ 272.900  Millions$ 630.900  Millions
Alpha Teknova Inc   40.09 %$ 4.885  Millions$ 12.185  Millions
Immucell Corporation  33.92 %$ 2.437  Millions$ 7.186  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.